Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2024 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) updated its FY 2024 earnings guidance on Thursday. The company provided earnings per share guidance of 3.650-4.050 for the period, compared to the consensus earnings per share estimate of 3.730. The company issued revenue guidance of $935.0 million-$1.0 billion, compared to the consensus revenue estimate of $947.3 million.

Analyst Upgrades and Downgrades

HALO has been the topic of several analyst reports. Wells Fargo & Company increased their price target on Halozyme Therapeutics from $48.00 to $58.00 and gave the company an overweight rating in a report on Friday, June 7th. JMP Securities lowered their price objective on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a market outperform rating on the stock in a research note on Wednesday, May 8th. HC Wainwright restated a buy rating and issued a $65.00 price objective on shares of Halozyme Therapeutics in a research note on Monday, June 24th. Piper Sandler downgraded shares of Halozyme Therapeutics from an overweight rating to a neutral rating and raised their price objective for the stock from $48.00 to $51.00 in a research note on Friday, June 7th. Finally, Benchmark raised their price objective on shares of Halozyme Therapeutics from $50.00 to $60.00 and gave the stock a buy rating in a research note on Tuesday. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Halozyme Therapeutics currently has a consensus rating of Moderate Buy and an average price target of $57.25.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $52.36 on Friday. The firm has a market capitalization of $6.66 billion, a P/E ratio of 21.64, a PEG ratio of 0.52 and a beta of 1.28. Halozyme Therapeutics has a 1 year low of $32.83 and a 1 year high of $53.00. The business has a 50-day moving average of $45.31 and a 200-day moving average of $40.46. The company has a current ratio of 6.64, a quick ratio of 5.36 and a debt-to-equity ratio of 8.44.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.07. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. The business had revenue of $195.88 million during the quarter, compared to analyst estimates of $201.72 million. On average, equities analysts anticipate that Halozyme Therapeutics will post 3.66 EPS for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $51.93, for a total value of $519,300.00. Following the sale, the chief financial officer now owns 15,480 shares in the company, valued at approximately $803,876.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders have sold 40,000 shares of company stock worth $1,858,100. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.